ebook_ADHD2019_spanish

16. Swanson JM. SNAP-IV 26-item teacher and parent rating scale. Hamilton: Collaborative Mental Health Care, [s. d.]. Disponível em: http://www.shared-care.ca/files/Scoring_for_SNAP_IV_Guide_26-item.pdf . Acesso em: 16 nov. 2018. 17. Bussing R, Fernandez M, Harwood M, Wei Hou, Garvan CW, Eyberg SM, et al. Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and norma- tive ratings from a school district sample. Assessment. 2008;15(3):317-28. 18. Murray DW, Bussing R, Fernandez M, Wei Hou, Garvan CW, Swanson JM, et al. Psychometric properties of teacher SKAMP ratings from a community sample. Assessment. 2009;16(2):193-208. 19. Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a labo- ratory school setting. Psychopharmacol Bull. 1998;34(1):47-53. 20. Coghill D, Lim SC, Gomez Flores L, Seth S, Dunlop G, Geddes A, et al. Dundee ADHD continuing care proforma (revised). Dundee: University of Dundee, 2015. Disponível em: https://discovery.dundee.ac.uk/en/ datasets/dundee-adhd-continuing-care-proforma-revised . Acesso em: 16 nov. 2018. 21. Swanson JM, Arnold LE, Molina BSG, Sibley MH, Hechtman LT, Hinshaw SP, et al. Young adult outco- mes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry. 2017;58(6):663-678. 22. Langley K, Fowler T, Ford T, Thapar AK, van den Bree M, Harold G, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2010;196(3):235-40. 23. Banaschewski T, Buitelaar J, Coghill DR, Sergeant JA, Sonuga-Barke E, Zuddas A, et al. The MTA at 8. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1120-1; author reply 1123-4. 24. Knaup C, Koesters M, Schoefer D, Becker T, Puschner B. Effect of feedback of treatment outcome in specialist mental healthcare: meta-analysis. Br J Psychiatry. 2009;195(1):15-22. 25. Craig SG, Davies G, Schibuk L, Weiss MD. Long-term effects of stimulant treatment for ADHD: what can we tell our patients? Current Developmental Disorders Reports. 2015;2(1):1-9. 26. Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs. 2016;30(7):603-28. 27. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs. 2008;22(3):213-37. 28. Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systema- tic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199-215. 29. March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol. 2000;28(6):527-41. 30. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guide- lines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173-96. 31. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2): 459-74, xi. Guía de la Federación Mundial de TDAH 123